

1 **Title:** *Salmonella* Enhances Osteogenic Differentiation in Adipose-Derived Mesenchymal Stem
2 Cells

3 **Running header:** *Salmonella* alters MSC differentiation trajectory

4 **Authors:** Soraya H. Foutouhi^{1,2#}, Nuradilla Mohamad-Fauzi^{3##*}, Dylan Bobby Storey^{1†}, Azarene
5 A. Foutouhi¹, Nguyet Kong^{1,2}, Amir Kol⁴, Dori Borjesson⁴, Prerak Desai^{1‡}, Jigna Shah^{1‡}, James
6 D. Murray^{1,3*}, and Bart C. Weimer^{1,2*}

7 ¹*Department of Population Health and Reproduction,*

8 ²*100K Pathogen Genome Project*

9 ³*Department of Animal Science,*

10 ⁴*Department of Pathology, Microbiology and Immunology,*

11 *University of California, Davis, CA, USA. 95616*

12 #co-first authors. Both contributed equally to this work.

13 **Current Addresses:** *University of Malaya, Institute of Ocean and Earth Sciences, Kuala
14 Lumpur, Malaysia; †West Sacramento, CA; ‡Janssen, Inc., Spring House, PN

15 ***Corresponding Authors:** Correspondence and requests for materials should be addressed to
16 JDM (jdmurray@ucdavis.edu) and BCW (bcweimer@ucdavis.edu).

17 **Author contributions:**

18 SHF: Conception and design, Collection and/or assembly of data, Data analysis and interpretation, Manuscript
19 writing; NMF: Conception and design, Collection and/or assembly of data, Data analysis and interpretation,
20 Manuscript writing; DS: Informatics, Data analysis and interpretation; PD: Collection and/or assembly of data;
21 JD: Collection and/or assembly of data; AAF: Administrative support, Collection and/or assembly of data; NK:
22 Administrative support, Collection and/or assembly of data; AK: Collection and/or assembly of data, Data analysis
23 and interpretation; DB: Study design, Provision of study material; JDM: Experiment conception and design,
24 Financial support, Administrative support, Provision of study material, Data analysis and interpretation, Manuscript
25 writing, Final approval of manuscript.; BCW: Experiment conception and design, Financial support,
26 Administrative support, Provision of study material, Data analysis and interpretation, Manuscript writing, Final
27 approval of manuscript.
28

29 **Abstract**

30 The potential of mesenchymal stem cells (MSCs) for tissue repair and regeneration has
31 garnered great attention. While MSC interaction with microbes at sites of tissue damage and
32 inflammation is likely, especially in the gut, the consequences of bacterial association have yet to
33 be elucidated. This study investigated the effect of *Salmonella enterica* ssp *enterica* serotype
34 Typhimurium on MSC trilineage differentiation path and mechanism. Through examination of
35 key markers of differentiation, immunomodulatory regulators, and inflammatory cytokines, we
36 demonstrated that *Salmonella* altered osteogenic and chondrogenic differentiation pathways in
37 human and goat adipose-derived MSCs. Gene expression profiles defined signaling pathway
38 alterations in response to *Salmonella* association not observed in epithelial cells. We uncovered
39 significant differential expression ($P < 0.05$) of genes associated with anti-apoptotic and pro-
40 proliferative responses in MSCs during *Salmonella* challenge. These observations led us to
41 conclude that bacteria, specifically *Salmonella*, induce pathways that influence functional
42 differentiation trajectories in MSCs, thus implicating substantial microbial influence on MSC
43 physiology and immune activity.

44 **Introduction**

45 Application of mesenchymal stem cells (MSCs) to regenerative medicine is an area of intensive
46 research [1, 2]. In addition to a capacity for self-renewal and differentiation into cartilage, bone,
47 and adipose tissue [3], MSCs home to sites of inflammation where they exhibit
48 immunomodulatory functions via secretion of paracrine factors [4, 5]. In cooperation with
49 recruited immune cells, MSCs moderate inflammation via expression of anti-inflammatory
50 cytokines [6-8], inhibit T-lymphocyte activation, and alter macrophages to express a regulatory
51 anti-inflammatory phenotype to increase phagocytic activity [5, 9]. Bacterial infections promote

52 inflammation and prompts MSCs to secrete anti-microbial peptides [10].

53 Microbial access to MSCs is likely at mucus membranes where tissue turnover is high and
54 immune-responsive cells infiltrate to control pathogens [11]. Inflammation, and subsequent
55 destruction of intestinal epithelial cells induces MSC recruitment to facilitate tissue recovery
56 [12]. While an apoptotic epithelial cell response to infection is well characterized [13], little is
57 known about the consequences of bacterial association on the behavior of stem cells. Treatment
58 of MSC with lipopolysaccharide (LPS) and *Escherichia coli* increases osteogenesis and
59 decreases adipogenesis; conversely, stimulation with *Staphylococcus aureus* decreases
60 osteogenesis and adipogenesis [14]. Recent discovery of invasion in MSCs by numerous bacteria
61 common in the oral cavity and gut resulted in augmentation of MSC inhibition of T-cell
62 proliferation and provides evidence of direct alteration of MSC immune function [15].
63 Maintenance of viability [15] and change in differentiation path [14] confirms that bacterial
64 association with MSCs not only varies in comparison to epithelial cells, but also altered function
65 beyond acute infection.

66 Host detection of microbial presence is accomplished in part by Toll-like receptors (TLRs),
67 which recognize bacterial components on their cell surface in epithelial cells are also expressed
68 in MSCs [16, 17]. It is not clear how pathogens regulate these molecules in MSCs. Tomchuck et
69 al. [18] reported the promotion of MSC migratory abilities, whereas a study by Pevsner-Fischer
70 [19] found TLR activation shifts lineage commitment to proliferation.

71 *Salmonella* pathogenesis in epithelial cells is primarily mediated via the type three-secretion
72 system [20, 21], which injects effector proteins that lead to apoptosis. These proteins target a
73 variety of host cell regulators, including the NF κ B pathway, leading to an inflammatory
74 environment that increases microbial internalization [21, 22]. Early transcription factors

75 implicated in MSC differentiation such as, peroxisome proliferator-activated receptor gamma
76 (PPARG) [23] and secreted phosphoprotein 1 (SPP1) [24], are involved in inflammation, and
77 may bridge cellular response to microbe-induced inflammation in MSCs. Previously unexplored
78 differences between the infectious route in epithelial cells and the immunomodulatory changes in
79 MSCs during host-pathogen interaction suggest substantial stem cell conditioning by *Salmonella*.
80 These novel observations led our group to hypothesize that microbial modulation of the immune
81 system in MSCs provides pathogens with an uncharted method of tissue infiltration, resulting in
82 undescribed biological impact.

83 In this study, it was hypothesized that human and goat MSCs internalize *Salmonella* that
84 resulted MSC altered trajectories towards a pro-osteogenic commitment, in parallel with the
85 induction of an anti-inflammatory, immunosuppressive cellular phenotype. Examination of
86 differentiation markers, immunomodulatory regulators and inflammatory cytokines demonstrated
87 that *Salmonella* was internalized without inducing MSC apoptosis that altered osteogenic and
88 chondrogenic differentiation. This phenomenon extended to alter molecular mechanisms of cell
89 survival, proliferation and immune regulation. These observations found microbial-specific
90 alterations in MSC differentiation and inflammatory status to influence stem cell fate and
91 functionality.

92 **Materials and Methods**

93 **Cell culture**

94 Human adipose-derived mesenchymal stem cells (hASCs) were isolated by the laboratory of Dr.
95 Dori Borjesson (University of California, Davis) and cultured in Minimum Essential Medium
96 Alpha Modification (MEM- α , HyClone) with 20% fetal bovine serum (FBS, HyClone) and 1%
97 penicillin-streptomycin (P/S, Gibco Life Technologies). Goat adipose-derived mesenchymal

98 stem cells (gASCs) were isolated by the laboratory of Dr. Matthew Wheeler (University of
99 Illinois, Urbana-Champaign), as described by Monaco et al. [25], and expanded as described by
100 Mohamad-Fauzi et al. [26]. ASCs were cultured in 5% CO₂/37°C, used at passage six. Colonic
101 epithelial cells (Caco-2; ATCC HTB-37) were obtained from American Type Culture Collection
102 (Manassas, VA) and grown as described by Shah et al. [27].

103 **Bacteria culture**

104 *Salmonella enterica* ssp *enterica* serotype Typhimurium LT2 (ST), 14028S, serotype Enteritidis
105 (BCW_4673), serotype Saint Paul (BCW_88) and serotype Newport (BCW_1378) were grown
106 in Luria-Bertani (LB) broth (Teknova, Holister, CA) and incubated with shaking (200 rpm) at
107 37°C. Cultures were grown as described by Kol et al. [15].

108 **Quantification of microbe association**

109 Association was determined using the gentamicin protection assay [28] and modified by Kol et
110 al. [15], with the following modifications: ASCs were plated (4×10^4) in a 96-well plate and
111 incubated overnight; bacteria were suspended in serum-free medium (10^8 CFU/ml) and added to
112 the ASCs (MOI 100:1).

113 **Transmission Electron Microscopy**

114 hASCs were plated on glass slides (Nalge Nuc International, Naperville, IL) and incubated for 2
115 h with ST [15]. Preparation and completion of transmission electron microscopy (TEM) was
116 conducted as outlined by Kol et al. [15].

117 **Differentiation**

118 Adipogenic and osteogenic differentiation was done using ASCs in 6-well plates at 2.5×10^5
119 ASCs/well and incubated with ST for 1 h as described above. Chondrogenic differentiation was
120 done in T-25 flasks at 3×10^5 ASCs/flask. Following treatment with gentamicin, ASCs were

121 washed with PBS and cultured for 48 hours in expansion medium to 70-80% confluence after
122 which differentiation medium was added.

123 **Osteogenic differentiation assay**

124 ASCs were cultured in osteogenic medium, fixed, rinsed and visualized under light and phase
125 microscopy as described in Mohamad-Fauzi et al. [26]. hASCs were cultured for 14 days,
126 whereas gASCs were cultured for 21 days. Control, non-induced cells were cultured in
127 expansion medium.

128 **Chondrogenic differentiation assay**

129 Chondrogenic differentiation was carried out as described by Zuk et al. [29]. Following ST
130 incubation, 70-80% confluent cells were trypsinized and suspended in expansion medium for 14
131 days and then processed and visualized as described by Mohamad-Fauzi et al. [26].

132 **Adipogenic differentiation assay**

133 Cells were cultured for 21 days in adipogenic induction medium, fixed, stained, and visualized as
134 described by Mohamad-Fauzi et al. [26].

135 **RNA extraction and cDNA synthesis**

136 ASCs were flash frozen prior to RNA extraction. For analysis of immunomodulatory factors,
137 ASCs were plated in 6-well plates (3×10^5 cells/well) and incubated with ST as described above.
138 Treatment with LPS (Sigma) was added at 10 ng/ml. MSCs were washed with PBS, and
139 immediately lysed with TRIzol Reagent (Life Technologies). Total RNA was extracted as
140 described by Mohamad-Fauzi et al. [26]. Total RNA (1 μ g) was used for first-strand cDNA
141 synthesis using SuperScript II Reverse Transcriptase (Life Technologies) and oligo-dT primers
142 according to the manufacturer.

143 **Quantitative RT-PCR**

144 Primers (Supplementary Tables 1-2) were designed using Primer3 if not obtained from
145 references. All primers spanned exon junctions or included introns. mRNA expression was
146 quantified using Fast SYBR Green reagent (Life Technologies) on the Bio-Rad CFX96 platform
147 (95°C for 20 seconds, 40 cycles of 95°C for 3 s and 60°C for 30 s), followed by melt curve
148 analysis. Gene expression was normalized to GAPDH using $2^{-\Delta\Delta CT}$ [30, 31]. Differences in
149 differentiation gene expression were calculated as fold-changes relative to cells cultured in
150 expansion medium (non-induced) and not treated with bacteria (non-treated). Inflammatory gene
151 expression was calculated as fold-changes relative to non-treated control cells. Treatments were
152 analyzed in pairwise comparisons using the Student's t-test on the software JMP (SAS Institute)
153 ($p \leq 0.05$). Data are presented as mean \pm SEM with three biological and technical replicates.

154 **GeneChip expression analyses**

155 Caco-2 infection samples with *Salmonella* LT2 were conducted using Affymetrix HGU133Plus2
156 GeneChip. Custom arrays containing all annotated coding and intergenic sequences of *Salmonella*
157 *enterica* spp. *enterica* sv Typhimurium LT2 [32-34]. Data were normalized using MS-RMA [35]
158 and analyzed using Significance Analysis of Microarrays (SAM) [33, 36].

159 **hASC RNA sequencing**

160 Total RNA (1 μ g) from hASCs was used to construct sequencing libraries with the Truseq
161 Stranded Total RNA LT Kit (Illumina). Quality of RNA and constructed libraries was
162 determined via 2100 Bioanalyzer. Libraries sequenced using an Illumina HiSeq2000 (BGI@UC
163 Davis, Sacramento, CA) with single-end 50 bp. Reads were aligned using the UCSC hg19
164 human reference genome ([ftp://igeneome:G3nom3s4u@ussd-](ftp://igeneome:G3nom3s4u@ussd-ftp.illumina.com/Homo_sapiens/UCSC/hg19/Homo_sapiens_UCSC_hg19.tar.gz)
165 ftp.illumina.com/Homo_sapiens/UCSC/hg19/Homo_sapiens_UCSC_hg19.tar.gz) and annotated

166 using "-a 10 --b2-very-sensitive -G". Read counts and normalization was done using Cufflinks
167 package (version 2.2.0) with flags "-u -G". Tables from cuffnorm and cuffdiff imported into
168 Ingenuity Pathway Analysis (IPA; Ingenuity Systems, version spring 2014). Sequence quality
169 was examined using Phred [Supplementary Figure S1A-B].

170 **Ingenuity Pathway Analysis**

171 IPA was used to determine biological pathways associated with gene expression profiles.
172 Networks represent molecular interaction based on the IPA knowledge database. Estimation of
173 probable pathway association was determined Fisher's exact test, and predicted direction change
174 was decided by the IPA regulation z-score algorithm (z-score ≥ 2 and ≤ -2 means a function is
175 significantly increased or decreased, respectively) [37].

176 **Results**

177 **Microbial association with adipose-derived mesenchymal stem cells**

178 Human and goat ASCs were susceptible to *Salmonella* infection *in vitro* [Figure 1],
179 which recapitulated previous observations in canine ASCs [15]. Total associated bacteria in both
180 organisms were invasive; gASCs showed significantly higher invasion compared to human cells
181 ($P = 0.006$) [Figure 1A]. Microbial association was not exclusive to ST; other *Salmonella*
182 serotypes also invaded ASCs, as did other organisms as our group demonstrated previously [15],
183 signifying a consistent trend in ASC vulnerability to common pathogens [Figure 1B]. Utilizing
184 TEM, intracellular ST were observed 2 h post hASC-microbe co-incubation [Figure 1C-F]. Cells
185 were not morphologically distressed nor apoptotic. In addition to invasion, ST adherence to
186 hASC cell surface was observed; this intimate association is consistent with other non-
187 pathogenic bacteria that Kol et al. [15] also observed.

188 As ST is the most common cause of enteric diarrhea, we limited additional studies to this

189 serotype. Following ST co-incubation, the expression of several immunomodulatory genes was
190 investigated [Figure 1G-H]. Interleukin 8 and 6 (*IL8*, *IL6*), prostaglandin-endoperoxide synthase
191 2 (*PTGS2*), nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (*NFKB1*),
192 transforming growth factor beta 1 (*TGFBI*), *PPARG* and *SPP1* were selected. gASCs and
193 hASCs treated with ST significantly increased *IL8* expression ($P \leq 0.033$, $P \leq 0.005$,
194 respectively). An increase in *IL8* was also observed in LPS-treated gASCs ($P \leq 0.0001$). LPS-
195 stimulated gASCs induced a significant increase in *IL6* ($P = 0.0001$), *PTGS2* ($P = 0.0009$),
196 *NFKB1* ($P = 0.0002$), *PPARG* ($P = 0.0204$), *SPP1* ($P = 0.037$) and *IL8* ($P \leq 0.0001$) gene
197 expression.

198 A broader analysis of gene expression using RNAseq found 118 significantly
199 differentially expressed genes in ST/hASCs interactions ($P \leq 0.05$, FDR = 0.1). Canonical
200 pathway analysis found hASCs treated with ST repressed cell death and survival genes
201 associated with apoptosis [Figure 2]. TNF/FasL pathway analysis [Figure S2] established the
202 muted apoptotic response in hASCs compared to Caco-2 cells following ST infection. Consistent
203 with viability post ST association, induced genes in hASCs included repression of apoptosis,
204 promotion of proliferation and multipotency [Figure 3.1]. Expression of heat shock protein B6
205 (*HSPB6*) and MAP-predicted activation of *v-akt* murine thymoma viral oncogene homolog 1
206 (*AKT1*) indicate promotion of hASC survival. *HSPB6* inhibits apoptosis of murine tumor cells,
207 and plays a role in cellular protection against oxidative damage [38, 39]. Activated in response to
208 a variety of cues, *AKT1* helps mediate cell survival and clonogenic potential [40-43].

209 Upregulated in ST-treated hASCs [Figure 3.1], parathyrosin (*PTMS*) is involved in
210 molecular organization, differentiation and proliferation; nuclear translocation of *PTMS* is
211 indicative of a pro-proliferative state [44, 45]. MAP predicted the repression of hedgehog

212 signaling (Hh), whose inhibition is reported to decrease MSC proliferation with no effect on
213 differentiation capacity [46]. We observed an increase in expression of patched 2 (*PTCH2*),
214 which influences epidermal differentiation and Hh activity, suggesting promotion of ASC
215 proliferation [47].

216 Superoxide dismutase 3 (*SOD3*) is pivotal for management of cellular redox [48-50] and
217 was induced in this study [Figure 3.2], which aligns with previous observations in INF γ /LPS-
218 activated microglial cells [48]. By promoting phagocytosis, EC-SOD facilitates bacteria
219 clearance and elicits an anti-inflammatory response to LPS induced inflammation and pulmonary
220 infection [51-53]. Interestingly, while Caco-2 cells strongly induced expression of TLR signaling
221 which facilitates the LPS response following pathogen challenge, this observation was not seen
222 in hASCs [Figure S3]. Using MAP, we focused on upstream regulators of *SOD3*, which may
223 have been responsible for its activation [Figure 3.2]. Both *SOX10* and heparin sulfate (HS), play
224 a role in the maintenance of multipotency and self-renewal [54, 55]. Interferon gamma (*INFG*)
225 influences the immunomodulatory effects of MSC, as *INFG*-activated MSCs suppress T-cells
226 and provide the necessary signal for MSC immunosuppression [56].

227 **Analysis of trilineage differentiation post-microbial association Chondrogenic** 228 **Differentiation**

229 ST treatment did not abate ASCs ability to undergo chondrogenesis. In hASCs,
230 differentiated cells migrated to form ridges that stained with Alcian Blue [Figure 4.2]. The
231 morphological changes in gASCs were more advanced compared to human cells after ridge
232 formation, cells aggregated, forming clumps that stained positive with Alcian Blue. Control, non-
233 induced cells remained in monolayer and exhibited minimal background staining.

234 Expression of SRY (sex determining region Y)-box 9 (*SOX9*), which is essential for

235 cartilage formation [57] and encodes for a transcription factor that promotes cartilage-specific
236 extracellular matrix components [58, 59], was measured 14-days post chondrogenic induction. In
237 hASCs, *SOX9* expression decreased ($P = 0.04$) in cells treated with ST [Figure 5.2]. Non-induced
238 hASCs treated with ST showed no significant change in *SOX9* expression. Chondrogenic
239 induction increased *SOX9* expression in hASCs compared to cells treated with control medium
240 ($P = 0.034$). gASCs showed a significant decrease in *SOX9* expression in induced and non-
241 induced ST-treated cells ($P = 0.027$, $P = 0.039$). There was a significant decrease in *SOX9*
242 expression between gASCs treated with induction ($P = 0.012$).

243 **Adipogenic Differentiation**

244 ASCs cultured in adipogenic medium accumulated lipid-filled vacuoles that stained with
245 Oil Red O [Figure 4.3]. Visually, no differences were observed between non-induced ST-treated
246 cells and the controls, which did not yield lipid-filled adipocytes nor stain with Oil Red O.

247 The lack of visual differentiation was further explored by examining expression of
248 *PPARG* and fatty acid binding protein 4 (*FABP4*) 21 days post-induction, which should detect
249 early events in adipogenesis [60, 61]. ST treatment of induced and non-induced hASCs did not
250 change *PPARG* expression [Figure 5.3], a trend consistent with gASCs; however, a significant
251 increase in *PPARG* expression in human and goat ASCs treated with differentiation vs. control
252 medium ($P \leq 0.0001$, $P \leq 0.0001$) was observed, as expected.

253 *FABP4* is a fatty acid binding protein specific to mammalian adipose tissue [62, 63]. No
254 significant difference was observed between induced ASCs treated with ST and non-treated
255 control cells. Non-induced hASCs, but not gASCs, treated with ST displayed a significant
256 increase in *FABP4* expression ($P = 0.019$). Both species induced *FABP4* in cells cultured in
257 adipogenic induction medium [Figure 5.3] ($P = 0.029$, $P \leq 0.0001$).

258 **Osteogenic Differentiation**

259 ASCs induced with osteogenic medium post ST treatment underwent osteogenesis.
260 Mineralized calcium deposits accumulated within the monolayer and stained with Alizarin Red S
261 [Figure 4.1]. By visual comparison, no difference was apparent between ST-treated and non-
262 treated cells. ASCs cultured in control, expansion medium did not undergo calcium
263 mineralization nor stain with Alizarin Red S, independent of ST treatment [Figure 4.1].

264 Collagen type I alpha 1 (*COL1A1*), alkaline phosphatase (*ALPL*) and *SPP1* expression
265 were determined at the termination of differentiation. *COL1A1* encodes for the major component
266 of the most abundant collagen found in bone matrix [64]. In hASCs induced for osteogenesis,
267 *COL1A1* expression was significantly higher in ST-treated cells compared to controls ($P =$
268 0.025) [Figure 5.1A]. No difference in expression was detected between non-induced ST-treated
269 and control hASCs. There was a significant decrease in *COL1A1* expression in hASCs treated
270 with osteogenic induction vs. control medium ($P \leq 0.0001$). gASCs displayed no significant
271 change of *COL1A1* expression in induced ST treated cells [Figure 5.1B]. There was a significant
272 decrease in *COL1A1* expression between gASCs treated with osteogenic induction vs. control
273 medium ($P = 0.018$).

274 *ALPL*, which provides phosphate ions for the production of bone mineral during matrix
275 maturation [65-67], increased in induced hASCs ($P = 0.02$) as well as ST treated-induced
276 hASCs. *ALPL* expression was 3.3-fold higher than in non-treated cells ($P = 0.03$) [Figure 5.1A].
277 In non-induced hASCs, no significant change in *ALPL* expression was detected following ST-
278 treatment. *ALPL* expression in gASCs was not detected.

279 *SPP1* is a non-collagenous bone protein expressed during the mineralization phase late in
280 osteogenesis [68]. In hASCs, *SPP1* was repressed in induced cells ($P \leq 0.0001$). *SPP1*

281 expression was 4.3-fold higher in induced hASCs treated with ST compared to non-treated cells
282 ($P = 0.002$). In non-induced hASCs, no difference in expression was observed between ST-
283 treated and control cells [Figure 5.1A]. In induced gASCs, no significant change in SPP1
284 expression was observed in ST-treated cells. However, a 7.2-fold increase in SPP1 was observed
285 in non-induced gASCs treated with ST compared to non-treated, non-induced controls ($P \leq 0.05$)
286 [Figure 5.1B].

287 Pretreatment of hASCs with ST followed by 14 days of osteogenic induction resulted in
288 the differential expression of 1060 genes (data not shown). RNAseq-IPA regulation z-score
289 algorithm identified associated downstream biological functions. Expression data projected the
290 repression of genes associated with cell-to-cell signaling, inflammation and response to
291 infectious disease [Figure 6.1], highlighting the potential anti-inflammatory phenotype of hASCs
292 subjected to microbial association (P -value ≤ 0.05 , z-score ≥ 2).

293 ST treatment followed by osteogenic differentiation also influenced genes involved in
294 cellular communication, migration and lineage commitment. Differentially expressed genes
295 included stanniocalcin 1 (*STCI*) and mesenchyme homeobox 2 (*MEOX2*) [Figure 6.2]. MSCs
296 secrete *STCI* in response to apoptotic signals [69]. *STCI* is reported to play a role in the
297 suppression of inflammation and may act in the regulation of calcium and phosphate homeostasis
298 [69, 70]. *STCI* expression was downregulated in differentiated hASCs pre-treated with ST.

299 Upregulated in ST treated osteogenic differentiated hASCs [Figure 6.2], chloride
300 intracellular channel 4 (*CLIC4*) is induced during cellular stress and influences cell cycle arrest
301 and apoptosis [71]. Intracellular chloride regulates cation transport and may be involved in
302 cellular signaling; *CLIC4* expression has been reportedly associated with Ca^{2+} induced
303 differentiation of keratinocytes [71, 72]. Macrophage migration inhibitory factor (MIF) is

304 elevated during tissue injury and inhibits MSC migration [73, 74]. Our data showed
305 downregulation of MIF expression [Figure 6.2]. Furthermore, adhesion to fibronectin through
306 $\alpha 5 \beta 1$ -integrin plays a part in the induction of MSC migration [75]. MSC expression of A1-3, B1,
307 and B3/4 integrins has been reported; blocking of B1 decreased migration in bone marrow-
308 derived MSCs [76, 77]. We detected an increase in A3, A4 and B1 integrins [Figure S5].

309 Induction of periostin (*POSTN*) following ST challenge [Figure 6.2] was observed. A
310 regulator of Wnt/ β -catenin signaling cascade and mediator of bone anabolism, *POSTN* increases
311 in response to stress and tissue damage [78, 79]. Wnt pathway activity is regulated by
312 extracellular factors, including heparin sulfate proteoglycans, and acts to control MSC
313 proliferation and differentiation [80]. hASCs treated with ST prior to induction displayed
314 downregulation of Wnt activator Secreted frizzled-related protein 1 (*SFRP1*) and induction of
315 transcription factors *JUN* and *AXIN2* [Figure S4A]. In addition, we observed a marked increase
316 in the expression of *TNFRSF11B* [Figure S4B]. Also known as osteoprotegerin, *TNFRSF11B* is
317 an anti-osteoclastogenic regulator, which is reported to augment osteogenesis [81].

318 Ephrin-B2 (*EFNB2*) is involved in osteogenic commitment and is required for
319 differentiation of osteoclasts and osteoblasts *in vivo* [82]. Upregulated in our data set [Figure
320 6.2], the *EFNB2* ligand and *EPHB4* receptor are reportedly expressed on the surface of MSCs
321 [82]. Increased expression of *COL1A2* was also detected [Figure 6.2]. *COL1A2* promotes cellular
322 proliferation and osteogenesis, a response in part regulated by ERK/AKT1 pathway activation
323 [83]. Activation of ERK mitogen activated protein kinase family (*MAPK*) drives the progression
324 of osteoblasts via phosphorylation of transcription factors [77]. Overlay of hASC gene
325 expression data illustrated upregulation of integrins involved in *MAPK1* activation as well as
326 intracellular signal transducer phosphatidylinositol-4,5-bisphosphate 3-kinase (*PI3K*) [Figure

327 S5].

328 Consistent with MSC ability to influence the immune response, we detected expression
329 of genes involved in MSC signaling and immunomodulation [Figure 6.2]. Cadherin 11 (*CDH11*)
330 expression was upregulated in our dataset. TGF β treatment increases expression of *CDH11* and
331 subsequent calcium-dependent cell-to-cell interactions in MSCs [84]. Engagement of *CDH11* on
332 fibroblast-like synoviocytes (FLS) has been reported to produce inflammatory mediators IL6 and
333 IL8 [84], though our transcriptome analysis did not indicate significant upregulation of either of
334 these cytokines. Kol et al. demonstrated that ST augments cMSCs ability to inhibit T-cell
335 proliferation [15]. In hASCs, we observed the differential expression of genes involved in the
336 suppression of immune cells; IPA regulator analysis highlighted the potential inhibitory effect of
337 ST-treated hASCs on phagocyte and granulocyte proliferation [Figure S6].

338 **Discussion**

339 Microbial presence on host tissue presents a wide range of beneficial to pathogenic
340 effects on cellular function. Intestinal bacteria have been shown to contribute to cellular
341 proliferation and development; observation of host and microbe interactions during inflammatory
342 and disease states have been imperative in refining our understating of healing and self-renewal
343 signaling mechanisms [85]. Studies on pathogen interference on MSC functionality demonstrate
344 the promising potential of stem cells as a mode of intercession for infection and inflammation.
345 Yuan et al [86] illustrated the ability of bone marrow-derived MSCs to increase clearance of
346 methicillin-resistant *Staphylococcus aureus* (MRSA) in a rat model; work by Maiti and
347 colleagues show that MSC stimulation with MRSA resulted not only in changes to cell
348 proliferation but also the induction of inflammatory markers [87]. Here, ASCs were susceptible
349 to microbial infection *in vitro* with many types of *Salmonella*, suggesting this is a common

350 characteristic, especially when taken with the observations of Kol et al. [15]. Our specific
351 investigation of ST resulted in changes in the expression of prototypical gene markers of
352 differentiation and inflammation, but not apoptosis.

353 Fiedler et al. [14] found continuous treatment with heat-inactivated *E. coli* slightly
354 increased ALPL activity in hASCs; heat-inactivation may have diminished the effect of bacterial
355 exposure. The migration of MSCs to sites of inflammation, where bacterial interaction may be
356 transient, could potentiate a narrow window of opportunity for microbial association. The use of
357 viable bacteria and shorter exposure time in this study may better mimic the physiological
358 conditions in which MSCs interact with microbes. We observed internalization of ST within 60
359 minutes of co-incubation; additional investigation is required to evaluate ST presence throughout
360 extended culture periods. ST pre-treatment did not abate the ability of ASCs to differentiate, but
361 did affect the expression of genes involved in osteogenesis and chondrogenesis.

362 ST treatment had a significant effect on osteogenic differentiation. In congruence with
363 Fiedler et al. [14], we observed an increase in *ALPL* expression in ST-treated hASCs induced for
364 osteogenesis. Increase in *ALPL* expression is consistent with the finding at 10 days post-
365 osteogenic induction in LPS-treated hASCs [16]. *ALPL* was not detected in gASCs, as cells were
366 harvested 21 days post-induction when the mineralization phase was likely occurring [88] and
367 *ALPL* expression may have decreased [67, 88].

368 Consistent with the lack of *ALPL*, upregulation of *SPP1* (a late marker of osteogenesis)
369 [88, 89], was observed in ST-treated gASCs. In addition to osteogenic commitment, the 6-
370 glycosylated phosphoprotein SPP1 has a significant role in cellular stress and immunity. As an
371 inflammatory mediator, SPP1 is reported as anti-inflammatory in acute colitis, while having an
372 opposite effect in chronic disease status [90, 91]. Plasma levels of SPP1 are elevated in Crohn's

373 disease and SPP1-deficient mice have an impaired ability to clear *Listeria monocytogenes* [90,
374 92]. The upregulation of *SPP1* observed implies a diverse series of biological effect on MSC
375 physiology. It is probable that the involvement of SPP1 in response to microbe-induced
376 inflammation results in the influence of ASCs towards osteogenesis.

377 Differential marker expression following ST treatment was heavily observed in non-
378 induced ASCs. Upregulation of *SPP1* was observed in ST-treated, non-induced gASCs, but not
379 in induced cells. It is possible that the osteoinductive effect of ST treatment in induced ASCs
380 was masked, as the medium contained additives that strongly induce osteogenesis. Pevsner-
381 Fischer et al. [19] observed a differential effect of LPS treatment on non-induced MSCs
382 compared to induced. Thus, the upregulation of osteogenic markers in non-induced cells
383 highlight the direct influence of microbial treatment on ASC lineage commitment.

384 We observed a concomitant decrease in chondrogenic differentiation in response to ST
385 treatment, as shown by a decrease in *SOX9* expression in ASCs. To our knowledge, this is the
386 first report on the direct effect of bacterial association on MSC chondrogenesis. *SOX9* is
387 required for commitment to chondrogenic lineage, thus murine *SOX9*-null cells do not express
388 markers of chondrogenesis [93]. Osteogenesis and chondrogenesis are tightly coupled processes
389 [94], both regulated by proteins in the TGF β superfamily [95]. An inverse relationship between
390 osteogenic and chondrogenic differentiation has been demonstrated; microRNAs targeting genes
391 important for osteogenesis were upregulated during chondrogenesis, and vice versa [96]. This
392 further supports the premise that ASCs pre-exposed to ST prior to induction favor characteristics
393 of osteogenic lineage commitment.

394 Exposure to whole bacteria and microbial components are sufficient to influence ASC
395 signaling. MSC response to microbial components is mediated by Toll-like receptors (TLRs);

396 hASCs express *TLR1-6* and *TLR9* [16]. TLR4 agonist LPS is a key component of the *Salmonella*
397 cell wall [97]. LPS influences osteogenesis in hASCs and bone marrow-derived MSCs (BM-
398 MSCs) by increasing mineralization, ALP activity, and expression of osteogenic markers [14, 16,
399 98, 99]. It is possible that LPS-induced changes in differentiation are mediated by TLRs and
400 thus, dependent on NFkB1 activation [99, 100]. In this study, we did not observe upregulation of
401 *NFKB1* expression following ST challenge or significant induction of genes involved in TLR
402 signaling pathway. As a rapid responder, NFkB1 proteins are available and inactive; activity
403 depends on phosphorylation-dependent degradation of NFkB1 inhibitors, thus the lack of change
404 in mRNA expression is not unexpected [101].

405 While the conditions of this study did not lead to an observed induction of TLR gene
406 expression, previous reports highlight the role of TLR activation in MSC physiology. TLR2
407 activation inhibited spontaneous adipogenic differentiation and increased osteogenesis in non-
408 induced mouse BM-MSCs, but inhibits trilineage differentiation in induced cultures [19]. The
409 upregulation of osteogenic markers in non-induced ST treated ASCs in this study supports this
410 observation. Furthermore, TLR-activated MSCs recruit immune cells; TLR-activated
411 macrophages secreted oncostatin M, a cytokine that induces osteogenic and inhibits adipogenesis
412 in BM-MSCs [102]. MSCs deficient in myeloid differentiation primary response 88 (*MYD88*),
413 which is crucial for TLR signaling [103], lack both osteogenic and chondrogenic potential [19],
414 providing further evidence for linking microbe-induced TLR signaling and osteochondrogenic
415 pathway induction.

416 Initiation of epithelial inflammation and rapid induction of pro-inflammatory cytokines
417 via calcium-mediated activation of NFkB1 in response to *Salmonella* is documented [104, 105].
418 A dose-dependent increase in IL8 secretion was reported in human BM-MSCs following LPS

419 treatment [106]. A hallmark of IL8 is the capacity for a variety of cells, including MSCs, to
420 rapidly express and secrete IL8 [107]. IL8 can inhibit osteoclasts bone resorption activity, and
421 stimulates osteoclast motility [108, 109]. Upregulation of *IL8* was detected after 14 days of
422 osteogenic media treatment [108]. In additional support of the coordination between
423 inflammatory and differentiation pathways, co-incubation with ST significantly increased *IL8*
424 expression in hASCs and gASCs.

425 Coordination between inflammation and lineage commitment likely involves various
426 small molecules. A pleiotropic cytokine, IL6 is involved in innate tissue response to injury and
427 maintenance of undifferentiated MSCs status, and *IL6* expression decreases during osteogenic
428 differentiation [110]. While mature osteoblasts displayed enhanced osteogenic differentiation,
429 primitive MSCs experienced a decrease in proliferation following IL6 treatment [111], implying
430 that IL6 influence on osteogenesis is complex and dependent on the status of targeted MSCs. In
431 this study, a significant increase in *IL6* expression was observed in LPS-treated gASCs. A
432 similar trend was noted in ST-treated gASCs and hASCs, although not statistically significant.
433 This suggests that ASC response to ST infection influences the secretion of small molecules
434 capable of cross-talk between inflammatory and differentiation pathways.

435 The transcriptome of hASCs post ST association alludes to a physiological shift in favor
436 of cell survival and proliferation. Under oxidative stress, MSCs display a reduced ability to
437 repair tissue and an increased propensity towards senescence [112, 113]. These conditions
438 decrease MSC capacity for osteogenesis in favor of adipogenic commitment [113]. Through
439 upregulation of redox mediators, hASCs appear to respond and mitigate oxidative stress, helping
440 to insure cell viability, multipotency, and promote immune suppression. As versatile immune
441 privileged cells, MSCs presented with microbial challenge may function as a safeguard,

442 contributing to an anti-inflammatory environment, which allows time and an atmosphere
443 conducive for infection clearance by resident phagocytes. However, it is unlikely that hASC
444 response to ST is without physiological consequences, as influence of inflammatory mediators
445 on lineage commitment appears to prime hASCs towards a pro-osteogenic phenotype.

446 The direct association of ASCs with ST influences key modulators of trilineage
447 differentiation. We illustrate that, as the pathways dictating MSC response to injury, microbial
448 products and inflammation overlap with the regulation of cellular differentiation, exposure to
449 bacteria alters lineage commitment. However, the extent and mechanisms responsible for
450 eliciting changes in MSC differentiation due to microbial interaction have yet to be fully
451 described. As ASCs are currently in contention as a powerful model for understanding the
452 complex interaction of pathogenesis, inflammation and calcification, further investigation into
453 the complex relationship between bacterial association and ASC physiology is imperative, as we
454 have established that this association results in distinctive changes to MSC physiology.

455 **Acknowledgments**

456 We thank Majlis Amanah Rakyat (Malaysia) and the Jastro Shields Research Fellowship,
457 and the USDA-CREES W2171 Regional Research Project for funding a portion of the work
458 described in this paper (NMF).

459

460 **References:**

- 461 1. Fossett, E. and W.S. Khan, *Optimising human mesenchymal stem cell numbers for*
462 *clinical application: a literature review*. Stem Cells Int, 2012. **2012**: p. 465259.
- 463 2. Marra, K.G. and J.P. Rubin, *The potential of adipose-derived stem cells in craniofacial*
464 *repair and regeneration*. Birth Defects Res C Embryo Today, 2012. **96**(1): p. 95-7.
- 465 3. Dominici, M., et al., *Minimal criteria for defining multipotent mesenchymal stromal*
466 *cells. The International Society for Cellular Therapy position statement*. Cytotherapy,
467 2006. **8**(4): p. 315-7.
- 468 4. Ortiz, L.A., et al., *Mesenchymal stem cell engraftment in lung is enhanced in response to*
469 *bleomycin exposure and ameliorates its fibrotic effects*. Proc Natl Acad Sci U S A, 2003.
470 **100**(14): p. 8407-11.
- 471 5. Balaji, S., S.G. Keswani, and T.M. Crombleholme, *The Role of Mesenchymal Stem Cells*
472 *in the Regenerative Wound Healing Phenotype*. Adv Wound Care (New Rochelle), 2012.
473 **1**(4): p. 159-165.
- 474 6. Roddy, G.W., et al., *Action at a distance: systemically administered adult*
475 *stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without*
476 *engraftment and primarily by secretion of TNF-alpha stimulated gene/protein 6*. Stem
477 Cells, 2011. **29**(10): p. 1572-9.
- 478 7. Galindo, L.T., et al., *Mesenchymal stem cell therapy modulates the inflammatory*
479 *response in experimental traumatic brain injury*. Neurol Res Int, 2011. **2011**: p. 564089.
- 480 8. Romieu-Mourez, R., et al., *Cytokine modulation of TLR expression and activation in*
481 *mesenchymal stromal cells leads to a proinflammatory phenotype*. J Immunol, 2009.
482 **182**(12): p. 7963-73.
- 483 9. Eggenhofer, E. and M.J. Hoogduijn, *Mesenchymal stem cell-educated macrophages*.
484 Transplant Res, 2012. **1**(1): p. 12.
- 485 10. Krasnodembskaya, A., et al., *Antibacterial effect of human mesenchymal stem cells is*
486 *mediated in part from secretion of the antimicrobial peptide LL-37*. Stem Cells, 2010.
487 **28**(12): p. 2229-38.
- 488 11. Xu, X.R., et al., *Dysregulation of mucosal immune response in pathogenesis of*
489 *inflammatory bowel disease*. World J Gastroenterol, 2014. **20**(12): p. 3255-64.
- 490 12. Semont, A., et al., *Mesenchymal stem cells increase self-renewal of small intestinal*
491 *epithelium and accelerate structural recovery after radiation injury*. Adv Exp Med Biol,
492 2006. **585**: p. 19-30.
- 493 13. Kim, J.M., et al., *Apoptosis of human intestinal epithelial cells after bacterial invasion*. J
494 Clin Invest, 1998. **102**(10): p. 1815-23.
- 495 14. Fiedler, T., et al., *Impact of bacteria and bacterial components on osteogenic and*
496 *adipogenic differentiation of adipose-derived mesenchymal stem cells*. Exp Cell Res,
497 2013. **319**(18): p. 2883-92.
- 498 15. Kol, A., et al., *Gastrointestinal microbes interact with canine adipose-derived*
499 *mesenchymal stem cells in vitro and enhance immunomodulatory functions*. Stem Cells
500 Dev, 2014. **23**(16): p. 1831-43.
- 501 16. Hwa Cho, H., Y.C. Bae, and J.S. Jung, *Role of toll-like receptors on human adipose-*
502 *derived stromal cells*. Stem Cells, 2006. **24**(12): p. 2744-52.
- 503 17. Raicevic, G., et al., *Inflammation modifies the pattern and the function of Toll-like*
504 *receptors expressed by human mesenchymal stromal cells*. Hum Immunol, 2010. **71**(3):

- 505 p. 235-44.
- 506 18. Tomchuck, S.L., et al., *Toll-like receptors on human mesenchymal stem cells drive their*
507 *migration and immunomodulating responses*. Stem Cells, 2008. **26**(1): p. 99-107.
- 508 19. Pevsner-Fischer, M., et al., *Toll-like receptors and their ligands control mesenchymal*
509 *stem cell functions*. Blood, 2007. **109**(4): p. 1422-32.
- 510 20. Rivera-Chavez, F., et al., *Salmonella uses energy taxis to benefit from intestinal*
511 *inflammation*. PLoS Pathog, 2013. **9**(4): p. e1003267.
- 512 21. Pilar, A.V., et al., *Active modification of host inflammation by Salmonella*. Gut Microbes,
513 2013. **4**(2): p. 140-5.
- 514 22. Thiennimitr, P., S.E. Winter, and A.J. Baumler, *Salmonella, the host and its microbiota*.
515 Curr Opin Microbiol, 2012. **15**(1): p. 108-14.
- 516 23. Pascual, G., et al., *A SUMOylation-dependent pathway mediates transrepression of*
517 *inflammatory response genes by PPAR-gamma*. Nature, 2005. **437**(7059): p. 759-63.
- 518 24. Sabo-Attwood, T., et al., *Osteopontin modulates inflammation, mucin production, and*
519 *gene expression signatures after inhalation of asbestos in a murine model of fibrosis*. Am
520 J Pathol, 2011. **178**(5): p. 1975-85.
- 521 25. Monaco, E., et al., *Morphological and transcriptomic comparison of adipose and bone*
522 *marrow derived porcine stem cells*. The Open Tissue Engineering & Regenerative
523 Medicine Journal, 2009. **2**: p. 20-33.
- 524 26. Mohamad-Fauzi, N., et al., *Impact of source tissue and ex vivo expansion on the*
525 *characterization of goat mesenchymal stem cells*. J Anim Sci Biotechnol, 2015. **6**(1): p. 1.
- 526 27. Shah, J., P.T. Desai, and B.C. Weimer, *Genetic mechanisms underlying the pathogenicity*
527 *of cold-stressed Salmonella enterica serovar typhimurium in cultured intestinal epithelial*
528 *cells*. Appl Environ Microbiol, 2014. **80**(22): p. 6943-53.
- 529 28. Elsinghorst, E.A., *Measurement of invasion by gentamicin resistance*. Methods Enzymol,
530 1994. **236**: p. 405-20.
- 531 29. Zuk, P.A., et al., *Multilineage cells from human adipose tissue: implications for cell-*
532 *based therapies*. Tissue Eng, 2001. **7**(2): p. 211-28.
- 533 30. Livak, K.J. and T.D. Schmittgen, *Analysis of relative gene expression data using real-*
534 *time quantitative PCR and the 2(-Delta Delta C(T)) Method*. Methods, 2001. **25**(4): p.
535 402-8.
- 536 31. Schmittgen, T.D. and K.J. Livak, *Analyzing real-time PCR data by the comparative C(T)*
537 *method*. Nat Protoc, 2008. **3**(6): p. 1101-8.
- 538 32. Shah, J., et al., *Preadaptation to cold stress in Salmonella enterica serovar Typhimurium*
539 *increases survival during subsequent acid stress exposure*. Appl Environ Microbiol,
540 2013. **79**(23): p. 7281-9.
- 541 33. Ng, K.M., et al., *Microbiota-liberated host sugars facilitate post-antibiotic expansion of*
542 *enteric pathogens*. Nature, 2013. **502**(7469): p. 96-9.
- 543 34. Marcobal, A., et al., *Bacteroides in the infant gut consume milk oligosaccharides via*
544 *mucus-utilization pathways*. Cell Host Microbe, 2011. **10**(5): p. 507-14.
- 545 35. Stevens, J.R., Balasubramanian Ganesan, Prerak Desai, Sweta Rao, and Bart C.
546 Weimer. . *Statistical issues for normalization of multi-species microarray data*. . in
547 *Nineteenth Annual Kansas State University Conference on Applied Statistics in*
548 *Agriculture*. . 2008. Kansas State University
- 549 36. Champine, P.J., et al., *Microarray analysis reveals potential mechanisms of BRMS1-*
550 *mediated metastasis suppression*. Clin Exp Metastasis, 2007. **24**(7): p. 551-65.

- 551 37. St-Pierre, C., et al., *Transcriptome sequencing of neonatal thymic epithelial cells*. Sci
552 Rep, 2013. **3**: p. 1860.
- 553 38. Ghulmiyyah, L.M., et al., *The role of oxidative stress in the developmental origin of adult*
554 *hypertension*. Am J Obstet Gynecol, 2011. **205**(2): p. 155 e7-11.
- 555 39. Chen, S., et al., *Heat shock protein B6 potently increases non-small cell lung cancer*
556 *growth*. Mol Med Rep, 2014. **10**(2): p. 677-82.
- 557 40. Gharibi, B., et al., *Inhibition of Akt/mTOR attenuates age-related changes in*
558 *mesenchymal stem cells*. Stem Cells, 2014. **32**(8): p. 2256-66.
- 559 41. Liu, P., et al., *Cell-cycle-regulated activation of Akt kinase by phosphorylation at its*
560 *carboxyl terminus*. Nature, 2014. **508**(7497): p. 541-5.
- 561 42. Song, G., G. Ouyang, and S. Bao, *The activation of Akt/PKB signaling pathway and cell*
562 *survival*. J Cell Mol Med, 2005. **9**(1): p. 59-71.
- 563 43. Xu, N., et al., *Akt: a double-edged sword in cell proliferation and genome stability*. J
564 Oncol, 2012. **2012**: p. 951724.
- 565 44. Hannappel, E. and T. Huff, *The thymosins. Prothymosin alpha, parathymosin, and beta-*
566 *thymosins: structure and function*. Vitam Horm, 2003. **66**: p. 257-96.
- 567 45. Okamoto, K. and F. Isohashi, *Purification and primary structure of a macromolecular-*
568 *translocation inhibitor II of glucocorticoid-receptor binding to nuclei from rat liver.*
569 *Inhibitor II is the 11.5-kDa Zn²⁺-binding protein (parathymosin)*. Eur J Biochem, 2000.
570 **267**(1): p. 155-62.
- 571 46. Plaisant, M., et al., *Inhibition of hedgehog signaling decreases proliferation and*
572 *clonogenicity of human mesenchymal stem cells*. PLoS One, 2011. **6**(2): p. e16798.
- 573 47. Adolphe, C., et al., *Patched 1 and patched 2 redundancy has a key role in regulating*
574 *epidermal differentiation*. J Invest Dermatol, 2014. **134**(7): p. 1981-90.
- 575 48. Kemp, K., et al., *Inflammatory cytokine induced regulation of superoxide dismutase 3*
576 *expression by human mesenchymal stem cells*. Stem Cell Rev, 2010. **6**(4): p. 548-59.
- 577 49. Kemp, K., et al., *Mesenchymal stem cell-secreted superoxide dismutase promotes*
578 *cerebellar neuronal survival*. J Neurochem, 2010. **114**(6): p. 1569-80.
- 579 50. Kwon, M.J., et al., *Role of superoxide dismutase 3 in skin inflammation*. J Dermatol Sci,
580 2012. **67**(2): p. 81-7.
- 581 51. Bowler, R.P., et al., *Extracellular superoxide dismutase attenuates lipopolysaccharide-*
582 *induced neutrophilic inflammation*. Am J Respir Cell Mol Biol, 2004. **31**(4): p. 432-9.
- 583 52. Kim, Y., et al., *Regulation of skin inflammation and angiogenesis by EC-SOD via HIF-*
584 *1alpha and NF-kappaB pathways*. Free Radic Biol Med, 2011. **51**(11): p. 1985-95.
- 585 53. Manni, M.L., et al., *Extracellular superoxide dismutase in macrophages augments*
586 *bacterial killing by promoting phagocytosis*. Am J Pathol, 2011. **178**(6): p. 2752-9.
- 587 54. Helledie, T., et al., *Heparan sulfate enhances the self-renewal and therapeutic potential*
588 *of mesenchymal stem cells from human adult bone marrow*. Stem Cells Dev, 2012.
589 **21**(11): p. 1897-910.
- 590 55. Shakhova, O. and L. Sommer, *Neural crest-derived stem cells*, in *StemBook*. 2008:
591 Cambridge (MA).
- 592 56. Sivanathan, K.N., et al., *Interferon-gamma modification of mesenchymal stem cells:*
593 *implications of autologous and allogeneic mesenchymal stem cell therapy in*
594 *allogeneic transplantation*. Stem Cell Rev, 2014. **10**(3): p. 351-75.
- 595 57. Bi, W., et al., *Sox9 is required for cartilage formation*. Nat Genet, 1999. **22**(1): p. 85-9.
- 596 58. Bell, D.M., et al., *SOX9 directly regulates the type-II collagen gene*. Nat Genet, 1997.

- 597 **16(2): p. 174-8.**
- 598 59. Han, Y. and V. Lefebvre, *L-Sox5 and Sox6 drive expression of the aggrecan gene in*
599 *cartilage by securing binding of Sox9 to a far-upstream enhancer.* Mol Cell Biol, 2008.
600 **28(16): p. 4999-5013.**
- 601 60. Shin, J., et al., *Comparative analysis of fatty acid-binding protein 4 promoters:*
602 *conservation of peroxisome proliferator-activated receptor binding sites.* J Anim Sci,
603 2009. **87(12): p. 3923-34.**
- 604 61. Shi, H., et al., *PPAR gamma Regulates Genes Involved in Triacylglycerol Synthesis and*
605 *Secretion in Mammary Gland Epithelial Cells of Dairy Goats.* PPAR Res, 2013. **2013:** p.
606 310948.
- 607 62. Bakhtiarizadeh, M.R., M. Moradi-Shahrbabak, and E. Ebrahimie, *Underlying functional*
608 *genomics of fat deposition in adipose tissue.* Gene, 2013. **521(1): p. 122-8.**
- 609 63. Bernlohr, D.A., et al., *Tissue specific expression of p422 protein, a putative lipid carrier,*
610 *in mouse adipocytes.* Biochem Biophys Res Commun, 1985. **132(2): p. 850-5.**
- 611 64. Viguet-Carrin, S., P. Garnero, and P.D. Delmas, *The role of collagen in bone strength.*
612 *Osteoporos Int*, 2006. **17(3): p. 319-36.**
- 613 65. de Bernard, B., et al., *Biochemical and immunohistochemical evidence that in cartilage*
614 *an alkaline phosphatase is a Ca²⁺-binding glycoprotein.* J Cell Biol, 1986. **103(4): p.**
615 **1615-23.**
- 616 66. Tenenbaum, H.C. and J.N. Heersche, *Differentiation of osteoblasts and formation of*
617 *mineralized bone in vitro.* Calcif Tissue Int, 1982. **34(1): p. 76-9.**
- 618 67. Choi, J.Y., et al., *Expression patterns of bone-related proteins during osteoblastic*
619 *differentiation in MC3T3-E1 cells.* J Cell Biochem, 1996. **61(4): p. 609-18.**
- 620 68. Nagata, T., et al., *Biosynthesis of bone proteins [SPP-1 (secreted phosphoprotein-1,*
621 *osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin)] in association with*
622 *mineralized-tissue formation by fetal-rat calvarial cells in culture.* Biochem J, 1991. **274**
623 **(Pt 2): p. 513-20.**
- 624 69. Kim, S.J., et al., *Stanniocalcin-1 protects retinal ganglion cells by inhibiting apoptosis*
625 *and oxidative damage.* PLoS One, 2013. **8(5): p. e63749.**
- 626 70. Block, G.J., et al., *Multipotent stromal cells are activated to reduce apoptosis in part by*
627 *upregulation and secretion of stanniocalcin-1.* Stem Cells, 2009. **27(3): p. 670-81.**
- 628 71. Suh, K.S., et al., *CLIC4, an intracellular chloride channel protein, is a novel molecular*
629 *target for cancer therapy.* J Invest Dermatol Symp Proc, 2005. **10(2): p. 105-9.**
- 630 72. Suh, K.S., et al., *CLIC4 mediates and is required for Ca²⁺-induced keratinocyte*
631 *differentiation.* J Cell Sci, 2007. **120(Pt 15): p. 2631-40.**
- 632 73. Xiong, C.J., et al., *Macrophage migration inhibitory factor inhibits the migration of*
633 *cartilage end plate-derived stem cells by reacting with CD74.* PLoS One, 2012. **7(8): p.**
634 **e43984.**
- 635 74. Fischer-Valuck, B.W., et al., *Migratory response of mesenchymal stem cells to*
636 *macrophage migration inhibitory factor and its antagonist as a function of colony-*
637 *forming efficiency.* Biotechnol Lett, 2010. **32(1): p. 19-27.**
- 638 75. Veevers-Lowe, J., et al., *Mesenchymal stem cell migration is regulated by fibronectin*
639 *through alpha5beta1-integrin-mediated activation of PDGFR-beta and potentiation of*
640 *growth factor signals.* J Cell Sci, 2011. **124(Pt 8): p. 1288-300.**
- 641 76. Ip, J.E., et al., *Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4*
642 *for myocardial migration and engraftment.* Mol Biol Cell, 2007. **18(8): p. 2873-82.**

- 643 77. Salasznyk, R.M., et al., *ERK signaling pathways regulate the osteogenic differentiation*
644 *of human mesenchymal stem cells on collagen I and vitronectin*. Cell Commun Adhes,
645 2004. **11**(5-6): p. 137-53.
- 646 78. Bonnet, N., S.J. Conway, and S.L. Ferrari, *Regulation of beta catenin signaling and*
647 *parathyroid hormone anabolic effects in bone by the matricellular protein periostin*. Proc
648 Natl Acad Sci U S A, 2012. **109**(37): p. 15048-53.
- 649 79. Cho, Y.H., et al., *Enhancement of MSC adhesion and therapeutic efficiency in ischemic*
650 *heart using lentivirus delivery with periostin*. Biomaterials, 2012. **33**(5): p. 1376-85.
- 651 80. Ling, L., V. Nurcombe, and S.M. Cool, *Wnt signaling controls the fate of mesenchymal*
652 *stem cells*. Gene, 2009. **433**(1-2): p. 1-7.
- 653 81. Palumbo, S. and W.J. Li, *Osteoprotegerin enhances osteogenesis of human mesenchymal*
654 *stem cells*. Tissue Eng Part A, 2013. **19**(19-20): p. 2176-87.
- 655 82. Tierney, E.G., et al., *High levels of ephrinB2 over-expression increases the osteogenic*
656 *differentiation of human mesenchymal stem cells and promotes enhanced cell mediated*
657 *mineralisation in a polyethyleneimine-ephrinB2 gene-activated matrix*. J Control Release,
658 2013. **165**(3): p. 173-82.
- 659 83. Tsai, K.S., et al., *Type I collagen promotes proliferation and osteogenesis of human*
660 *mesenchymal stem cells via activation of ERK and Akt pathways*. J Biomed Mater Res A,
661 2010. **94**(3): p. 673-82.
- 662 84. Park, S.J., et al., *Interaction of mesenchymal stem cells with fibroblast-like synoviocytes*
663 *via cadherin-11 promotes angiogenesis by enhanced secretion of placental growth factor*.
664 J Immunol, 2014. **192**(7): p. 3003-10.
- 665 85. Sun, J., *Enteric bacteria and cancer stem cells*. Cancers (Basel), 2010. **3**(1): p. 285-97.
- 666 86. Yuan, Y., et al., *Marrow mesenchymal stromal cells reduce methicillin-resistant*
667 *Staphylococcus aureus infection in rat models*. Cytotherapy, 2014. **16**(1): p. 56-63.
- 668 87. Maiti, A. and W.A. Jiranek, *Inhibition of Methicillin-resistant Staphylococcus aureus-*
669 *induced cytokines mRNA production in human bone marrow derived mesenchymal stem*
670 *cells by 1,25-dihydroxyvitamin D3*. BMC Cell Biol, 2014. **15**: p. 11.
- 671 88. Owen, T.A., et al., *Progressive development of the rat osteoblast phenotype in vitro:*
672 *reciprocal relationships in expression of genes associated with osteoblast proliferation*
673 *and differentiation during formation of the bone extracellular matrix*. J Cell Physiol,
674 1990. **143**(3): p. 420-30.
- 675 89. Cowles, E.A., et al., *Mineralization and the expression of matrix proteins during in vivo*
676 *bone development*. Calcif Tissue Int, 1998. **62**(1): p. 74-82.
- 677 90. Wang, K.X. and D.T. Denhardt, *Osteopontin: role in immune regulation and stress*
678 *responses*. Cytokine Growth Factor Rev, 2008. **19**(5-6): p. 333-45.
- 679 91. Zou, C., et al., *Osteopontin promotes mesenchymal stem cell migration and lessens cell*
680 *stiffness via integrin beta1, FAK, and ERK pathways*. Cell Biochem Biophys, 2013.
681 **65**(3): p. 455-62.
- 682 92. Ashkar, S., et al., *Eta-1 (osteopontin): an early component of type-1 (cell-mediated)*
683 *immunity*. Science, 2000. **287**(5454): p. 860-4.
- 684 93. Akiyama, H., *Control of chondrogenesis by the transcription factor Sox9*. Mod
685 Rheumatol, 2008. **18**(3): p. 213-9.
- 686 94. Joyce, M.E., et al., *Transforming growth factor-beta and the initiation of chondrogenesis*
687 *and osteogenesis in the rat femur*. J Cell Biol, 1990. **110**(6): p. 2195-207.
- 688 95. Wan, M. and X. Cao, *BMP signaling in skeletal development*. Biochem Biophys Res

- 689 Commun, 2005. **328**(3): p. 651-7.
- 690 96. Suomi, S., et al., *MicroRNAs regulate osteogenesis and chondrogenesis of mouse bone*
691 *marrow stromal cells*. Gene Regul Syst Bio, 2008. **2**: p. 177-91.
- 692 97. Hoshino, K., et al., *Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are*
693 *hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product*. J
694 Immunol, 1999. **162**(7): p. 3749-52.
- 695 98. Raicevic, G., et al., *Inflammation and Toll-like receptor ligation differentially affect the*
696 *osteogenic potential of human mesenchymal stromal cells depending on their tissue*
697 *origin*. Tissue Eng Part A, 2012. **18**(13-14): p. 1410-8.
- 698 99. Cho, H.H., et al., *NF-kappaB activation stimulates osteogenic differentiation of*
699 *mesenchymal stem cells derived from human adipose tissue by increasing TAZ*
700 *expression*. J Cell Physiol, 2010. **223**(1): p. 168-77.
- 701 100. Kawai, T. and S. Akira, *Signaling to NF-kappaB by Toll-like receptors*. Trends Mol Med,
702 2007. **13**(11): p. 460-9.
- 703 101. Oeckinghaus, A. and S. Ghosh, *The NF-kappaB family of transcription factors and its*
704 *regulation*. Cold Spring Harb Perspect Biol, 2009. **1**(4): p. a000034.
- 705 102. Guihard, P., et al., *Induction of osteogenesis in mesenchymal stem cells by activated*
706 *monocytes/macrophages depends on oncostatin M signaling*. Stem Cells, 2012. **30**(4): p.
707 762-72.
- 708 103. Kawai, T., et al., *Unresponsiveness of MyD88-deficient mice to endotoxin*. Immunity,
709 1999. **11**(1): p. 115-22.
- 710 104. Gewirtz, A.T., et al., *Salmonella typhimurium induces epithelial IL-8 expression via*
711 *Ca(2+)-mediated activation of the NF-kappaB pathway*. J Clin Invest, 2000. **105**(1): p.
712 79-92.
- 713 105. Eckmann, L., M.F. Kagnoff, and J. Fierer, *Epithelial cells secrete the chemokine*
714 *interleukin-8 in response to bacterial entry*. Infect Immun, 1993. **61**(11): p. 4569-74.
- 715 106. Rougier, F., et al., *IL-6 and IL-8 production by human bone marrow stromal cells*.
716 Cytokine, 1998. **10**(2): p. 93-7.
- 717 107. Hoffmann, E., et al., *Multiple control of interleukin-8 gene expression*. J Leukoc Biol,
718 2002. **72**(5): p. 847-55.
- 719 108. Sumanasinghe, R.D., et al., *Expression of proinflammatory cytokines by human*
720 *mesenchymal stem cells in response to cyclic tensile strain*. J Cell Physiol, 2009. **219**(1):
721 p. 77-83.
- 722 109. Fuller, K., J.M. Owens, and T.J. Chambers, *Macrophage inflammatory protein-1 alpha*
723 *and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts*. J
724 Immunol, 1995. **154**(11): p. 6065-72.
- 725 110. Pricola, K.L., et al., *Interleukin-6 maintains bone marrow-derived mesenchymal stem cell*
726 *stemness by an ERK1/2-dependent mechanism*. J Cell Biochem, 2009. **108**(3): p. 577-88.
- 727 111. Cho, T.J., et al., *Expression and role of interleukin-6 in distraction osteogenesis*. Calcif
728 Tissue Int, 2007. **80**(3): p. 192-200.
- 729 112. Zhu, W., et al., *Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem*
730 *cells*. Stem Cells, 2006. **24**(2): p. 416-25.
- 731 113. Kim, D.H., et al., *Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem*
732 *cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in*
733 *PPARgamma*. Stem Cells Dev, 2010. **19**(12): p. 1863-73.

734

735 **Figure Legends:**

736 **Figure 1: Microbial Association with human and goat ASCs (A-F).** ASCs presented a
737 uniform pattern of *Salmonella enterica ssp enterica* serotype Typhimurium LT2 (ST)
738 infection, the total associated bacteria were invaded, gASC show significantly higher invasion
739 compared to human cells (A). ASCs susceptibility to invasion was not exclusive to ST,
740 association patterns were microbe specific; 35%, 12% *Salmonella enterica ssp enterica* serotype
741 Typhimurium 14028, and 25%, 100% *Salmonella enterica ssp enterica* serotype Enteritidis
742 (BCW_4673) were invaded in goat and human ASCs respectively (B). In gASCs, 35%
743 *Salmonella enterica ssp enterica* serotype Newport (BCW_1378) and in hASCs, 7% of
744 *Salmonella enterica ssp enterica* serotype Saint Paul (BCW_88) were invaded (B). Intracellular
745 ST was observed by TEM two hours post MSC co-incubation (D-F), consistent with control non-
746 treated hASCs (C), ST infected cells showed no signs of cellular toxicity (D-F). ST adherence to
747 hASC was observed at various sites (E-F). **Expression of immunomodulatory factors in ASCs**
748 **post-microbial association (G-H).** Quantitative PCR analysis of IL6, PTGS2, NFKB1, TGFB1,
749 PPARG, SPP1, and IL8 expression in (G) goat and (H) human ASCs treated with ST or LPS.
750 Data is presented as fold change (\pm SEM) in relative to expression levels in non-treated cells
751 ("C") (fold change \sim 1, indicated by the dotted line). Statistical significance of $P < 0.05$ is
752 denoted by an asterisk (*), and $P < 0.01$ denoted by two asterisks (**).

753 **Figure 2: Downstream trends analysis of differentially expressed genes in hASCs post**
754 **microbial challenge.** The IPA regulation z-score algorithm was used to identify biological
755 functions expected to increase or decrease based on the gene expression changes described in our
756 dataset. Predictions base on p-value and z-score; positive z-score implies an increase in the
757 predicted function, a negative z-score a decrease (z-score ≥ 2 or ≤ -2 represented by orange
758 dotted lines). P-values ≤ 0.05 (red dots determined by Fischer's exact test), illustrate a significant

759 association between a given biological function and genes differentially expressed in our dataset
760 ($P \leq 0.05$).

761 **Figure 3.1: Network displays interactions between genes regulating cell cycle, cellular**
762 **assembly and organization that were differentially expressed in hASCs treated for sixty**
763 **minutes with ST compared with untreated control.** Upregulated genes are colored in shades
764 of red, down regulated in shades of green ($P \leq 0.05$). IPA inserted Genes in white because they
765 are connected to this network; dashed and solid lines denote indirect and direct relationships
766 between molecules. The IPA molecule activity predictor assessed the activity of molecules
767 strongly connected to this network; blue and orange colored molecules are predicted to have
768 decreased and increased activity, respectively.

769 **Figure 3.2: Up regulation of superoxide dismutase 3 (SOD3) in hASCs following microbial**
770 **challenge.** The IPA molecule activity predictor assessed the activity of molecules strongly
771 connected to SOD3 (colored in shade or red); orange colored molecules are predicted to have an
772 increased activity, based on the increased expression of SOD3 in our dataset. IPA inserted Genes
773 colored in white because they are connected to this network; dashed and solid lines denote
774 indirect and direct relationships between molecules.

775 **Figure 4: Trilineage staining of human and goat ASCs.** Alizarin Red S staining of osteogenic
776 differentiation in ASCs post-microbial association (4.1). hASCs (A-D) were cultured in
777 osteogenic differentiation medium for 14 days, whereas gASCs (E-H) for 21 days and stained
778 with Alizarin Red S. ASCs cultured in osteoinductive medium stained positive for calcium, (A-B
779 and E-F, respectively), but did not stain when cultured in control medium (C-D and G-H,
780 respectively), regardless of ST treatment. Representative images are shown in phase contrast at
781 40X magnification (scale bars represent 500 μm). Figure 4.2. Alcian Blue staining of

782 chondrogenic differentiation in ASCs post-microbial association. Human (A-D) and goat (E-H)
783 ASCs were cultured in chondrogenic differentiation medium for 14 days, and subsequently
784 stained with Alcian Blue. Cellular condensation, as well ridge and micromass formations that
785 stain positive was observed in human and goat ASCs induced for chondrogenesis (A-B and E-F,
786 respectively), independent of ST treatment. Some background staining was observed in ST-
787 treated and non-treated cells cultured in control medium, but cells remained in monolayer (C-D
788 and G-H, respectively). Representative images are shown in phase contrast at 40X magnification
789 (scale bars represent 500 μm). Figure 4.3 Oil Red O staining of adipogenic differentiation in
790 ASCs post-microbial association. hASCs (A-D) and gASCs (E-H) were cultured in adipogenic
791 induction medium for 21 days, and stained with Oil Red O. Accumulation of cytoplasmic lipid
792 droplets were observed in ASCs induced for adipogenesis (A-B and E-F, respectively),
793 independent of ST treatment. ST-treated and non-treated ASCs cultured in control medium did
794 not yield lipid-positive cells (C-D and G-H, respectively). Representative images are shown in
795 bright field at 200X magnification (scale bars represent 100 μm).









796 **Figure 5: ASC expression of trilineage differentiation markers.** Figure 5.1 Expression of
797 osteogenic markers in ASCs post-microbial association. Quantitative PCR analysis of COL1A1,
798 ALPL and SPP1 gene expression in A) human and B) goat ASCs induced with osteogenic
799 differentiation medium and/or treated with S.T. Figure 5.2 Expression of chondrogenic markers
800 post-microbial association. Quantitative PCR analysis of SOX9 expression in A) human and B)
801 goat ASCs induced with chondrogenic differentiation medium and/or treated with S.T. Figure
802 5.3 Expression of adipogenic markers in ASCs post-microbial association. Quantitative PCR
803 analysis of PPARG and FABP4 expression in A) human and B) goat ASCs induced with
804 adipogenic induction medium and/or treated with ST. Data is presented as fold change (\pm SEM)


805 relative to expression levels in non-treated, non-induced cells (fold change ~ 1 , indicated by the
806 dotted line). Statistical significance of $P < 0.05$ is denoted by an asterisk (*), and $P < 0.01$
807 denoted by two asterisks (**).

808 **Figure 6.1: Downstream trends analysis of differentially expressed genes in hASCs induced**
809 **towards osteogenesis post microbial challenge.** The IPA regulation z-score algorithm was used
810 to identify biological functions expected to increase or decrease based on the gene expression
811 changes observed in our dataset. Predictions base on p-value and z-score; positive z-score
812 implies an increase in the predicted function, a negative z-score a decrease (z-score ≥ 2 or ≤ -2
813 represented by orange dotted lines). P-values ≤ 0.05 (red dots determined by Fischer's exact test),
814 illustrate a significant association between a given biological function and genes differentially
815 expressed in our dataset ($P \leq 0.05$).

816 **Figure 6.2: Network displays interactions between genes involved in cell signaling,**
817 **migration and differentiation that were differentially expressed in hASCs induced towards**
818 **an osteogenic lineage following ST challenge.** Up-regulated genes are colored in shades of red,
819 down-regulated in shades of green. Genes in white were inserted by IPA because they are
820 connected to this network; dashed and solid lines denote indirect and direct relationships
821 between molecules. The IPA molecule activity predictor assessed the activity of molecules
822 strongly connected to this network; blue and orange colored molecules are predicted to have
823 decreased and increased activity, respectively.

824





Path Designer Shapes


- Complex/Group/Other
- Chemical/Toxicant
- Cytokine/Growth Factor
- Disease
- Drug
- Enzyme
- Function
- G-protein Coupled Receptor
- Ion Channel
- Kinase
- Ligand-dependent Nuclear Receptor
- Mature microRNA
- microRNA
- Peptidase
- Phosphatase
- Transcription Regulator
- Translation Regulator
- Transmembrane Receptor
- Transporter


Prediction Legend

more extreme	less
Upregulated	
Downregulated	
more confidence	less
Predicted activation	
Predicted inhibition	

Predicted Relationships

- Leads to activation
- Leads to inhibition
- Findings inconsistent with state of downstream molecule
- Effect not predicted





Path Designer Shapes


- Complex/Group/Other
- Chemical/Toxicant
- Cytokine/Growth Factor
- Disease
- Drug
- Enzyme
- Function
- G-protein Coupled Receptor
- Ion Channel
- Kinase
- Ligand-dependent Nuclear Receptor
- Mature microRNA
- microRNA
- Peptidase
- Phosphatase
- Transcription Regulator
- Translation Regulator
- Transmembrane Receptor
- Transporter


Prediction Legend




more extreme	less
Upregulated	
Downregulated	
more confidence	less
Predicted activation	
Predicted inhibition	

Predicted Relationships

- Leads to activation
- Leads to inhibition
- Findings inconsistent with state of downstream molecule
- Effect not predicted









5.1

A




B




5.2

A




B




5.3

A



B



6.1

